5-Fluorouracil 0.5% and salicylic acid 10.0% (Actikerall)

In Canada, 74,100 new cases of non-melanoma skin cancers (NMSCs) and 270 deaths due to these cancers were predicted for 2011.2 AK typically manifests as 2 mm to 6 mm scaly macules, papules, or plaques that are skin to reddish-brown in colour, and may be flat or thickened (hyperkeratotic).4,5 Patient...

Full description

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2017, 2017
Series:Common drug review
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 03417nam a2200289 u 4500
001 EB001839403
003 EBX01000000000000001003392
005 00000000000000.0
007 tu|||||||||||||||||||||
008 180702 r ||| eng
245 0 0 |a 5-Fluorouracil 0.5% and salicylic acid 10.0% (Actikerall)  |h Elektronische Ressource 
260 |a Ottawa (ON)  |b Canadian Agency for Drugs and Technologies in Health  |c 2017, 2017 
300 |a 1 online resource  |b illustrations 
505 0 |a Includes bibliographical references 
653 |a Fluorouracil / administration & dosage 
653 |a Salicylic Acid / administration & dosage 
653 |a Keratosis, Actinic / drug therapy 
653 |a Treatment Outcome 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a Common drug review 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK476506  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
082 0 |a 610 
520 |a In Canada, 74,100 new cases of non-melanoma skin cancers (NMSCs) and 270 deaths due to these cancers were predicted for 2011.2 AK typically manifests as 2 mm to 6 mm scaly macules, papules, or plaques that are skin to reddish-brown in colour, and may be flat or thickened (hyperkeratotic).4,5 Patients with AK are usually referred to dermatologists and diagnosis is frequently made on clinical appearance alone.1 A skin biopsy may be required when there is clinical doubt or suspicion of invasive malignancy.1,5 Detectable AK may be associated with a field change where the surrounding skin is also altered and subclinical lesions may be present.2 Patient input to the CADTH Common Drug Review (CDR) suggests that cosmetic issues are a major concern for patients, and this can have a negative impact on self-confidence. The submitted product is a combination of two topical therapies, 5-fluorouracil 0.5% (5-FU) and salicylic acid 10% (SA).  
520 |a According to the British Association of Dermatologists, 15% to 25% of actinic keratosis (AK) lesions spontaneously resolve during a one-year period.1 However, AK lesions may develop into invasive squamous cell carcinoma (SCC) if left untreated.2 The rate of progression from AK to SCC is unknown. Mathematical models derived from a study predicted that for an individual with an average of 7.7 AKs, the probability of developing an SCC at the same or nearby site within a 10-year period is approximately 10.3 The risk of malignant transformation is higher in patients who are immunocompromised.  
520 |a 5-FU is an antimetabolite that is already approved as monotherapy for treatment of AK, although at a concentration of 5%. SA is a keratolytic, and the theory behind its use is to improve penetration of the combination in hyperkeratotic AK. The 5-FU/SA combination under review is administered once daily to affected lesions, until lesions have cleared or for a maximum of 12 weeks. It is indicated for the management of grade I/II hyperkeratotic AK. The objective of this report was to perform a systematic review of the beneficial and harmful effects of 5-FU (0.5%) combined with SA 10% applied topically once daily for the topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (grade I/II) of the face, forehead, and balding scalp in immunocompetent adult patients